Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2016-02-05
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 276
- Registration Number
- NCT00893373
- Locations
- 🇩🇪
Sozialstiftung Bamberg Klinikum am Bruderwald, Bamberg, Germany
🇩🇪Klinikum Bayreuth, Bayreuth, Germany
🇩🇪Charite Campus Benjamin Franklin, Berlin, Germany
Sorafenib-RT Treatment for Liver Metastasis (SLIM)
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 54
- Registration Number
- NCT00892424
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 24
- Registration Number
- NCT00892658
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
Sorafenib in Relapsed High Grade Osteosarcoma
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2013-03-28
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 35
- Registration Number
- NCT00889057
- Locations
- 🇮🇹
Istituto Nazionale Tumori - Unit of Medical Oncology, Milano, Italy
🇮🇹I.R.C.C. - Unit of Medical Oncology, Candiolo, Torino, Italy
🇮🇹Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, Italy
Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-04-28
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- AIO-Studien-gGmbH
- Target Recruit Count
- 101
- Registration Number
- NCT00889343
- Locations
- 🇩🇪
Friedrich-Ebert-Krankenhaus Neumünster, Klinik für Hämatologie, Onkologie und Nephrologie, Neumünster, Schleswig-Holstein, Germany
🇩🇪Hämatologisch-onkologische Praxis Dr. med. Peter Schmidt, Neunkirchen, Saarland, Germany
🇩🇪Medizinisches Versorgungszentrum am Siloah St. Trudpert Klinikum, Pforzheim, Baden-Würtemberg, Germany
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2011-07-13
- Lead Sponsor
- Aegera Therapeutics
- Target Recruit Count
- 75
- Registration Number
- NCT00882869
- Locations
- 🇨🇳
Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong, China
🇨🇳Queen Elizabeth Hospital, Hong Kong, China
🇨🇳Queen Mary Hospital, Hong Kong, China
Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2020-08-10
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00880542
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
- First Posted Date
- 2009-04-03
- Last Posted Date
- 2017-02-07
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 11
- Registration Number
- NCT00875615
- Locations
- 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 60
- Registration Number
- NCT00872014
Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2009-03-27
- Last Posted Date
- 2013-11-03
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 52
- Registration Number
- NCT00870532
- Locations
- 🇸🇬
National Cancer Centre, Singapore, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.